NFE2L2 and obesity disorder: Serpina3c inhibits the Hif1α-glycolysis pathway and reduces de novo lipogenesis and lactic acid secretion in adipocytes by binding to Nrf2, ultimately ameliorating obesity, hypertriglyceridemia, and metaflammation induced by HFD.